Biocon has entered into an out-licensing agreement with Ajanta Pharma to market its vertically integrated drug product, Semaglutide, in 26 countries. Ajanta Pharma gains exclusive marketing rights in 23 countries and semi-exclusive rights in 3 countries across Africa, the Middle East, and Central Asia. This collaboration expands the reach of Semaglutide, a drug used to improve glycemic control in adults with type-2 diabetes, into new markets.
Semaglutide Agreement
Biocon Limited has announced an out-licensing agreement with Ajanta Pharma Ltd for Semaglutide. The agreement, announced on December 23, 2025, grants Ajanta Pharma the rights to market Semaglutide in 26 countries. This strategic partnership aims to expand the global reach of this important diabetes medication.
Territorial Rights
Under the agreement, Biocon will supply Semaglutide to Ajanta Pharma. Ajanta gains exclusive marketing rights for the product in 23 countries. They also receive semi-exclusive marketing rights in 3 countries. These regions include areas across Africa, the Middle East, and Central Asia.
Strategic Rationale
According to Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Ltd., this partnership with Ajanta Pharma is a strategic step in expanding the global footprint of Biocon’s GLP-1 portfolio and maximizing the value of our scientific investments in complex peptide development. The collaboration leverages Ajanta’s commercial reach to accelerate market access. It also enables broader and more affordable access to Semaglutide.
Ajanta’s Perspective
Yogesh Agrawal, Managing Director, Ajanta Pharma Ltd, commented that GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. He expressed excitement in partnering with Biocon for Semaglutide, aiming to build it into a meaningful and high-growth brand across the specified countries.
Source: BSE
